Mutations in PINK1 and PARK2 cause autosomal recessive parkinsonism, a neurodegenerative disorder that is characterized by the loss of dopaminergic neurons. To discover potential therapeutic pathways, we identified factors that genetically interact with Drosophila park and Pink1. We found that overexpression of the translation inhibitor Thor (4E-BP) can suppress all of the pathologic phenotypes, including degeneration of dopaminergic neurons in Drosophila. 4E-BP is activated in vivo by the TOR inhibitor rapamycin, which could potently suppress pathology in Pink1 and park mutants. Rapamycin also ameliorated mitochondrial defects in cells from individuals with PARK2 mutations. Recently, 4E-BP was shown to be inhibited by the most common cause of parkinsonism, dominant mutations in LRRK2. We also found that loss of the Drosophila LRRK2 homolog activated 4E-BP and was also able to suppress Pink1 and park pathology. Thus, in conjunction with recent findings, our results suggest that pharmacologic stimulation of 4E-BP activity may represent a viable therapeutic approach for multiple forms of parkinsonism.
Mutations in PINK1 and PARK2 cause autosomal recessive parkinsonism, a neurodegenerative disorder that is characterized by the loss of dopaminergic neurons. To discover potential therapeutic pathways, we identified factors that genetically interact with Drosophila park and Pink1. We found that overexpression of the translation inhibitor Thor (4E-BP) can suppress all of the pathologic phenotypes, including degeneration of dopaminergic neurons in Drosophila. 4E-BP is activated in vivo by the TOR inhibitor rapamycin, which could potently suppress pathology in Pink1 and park mutants. Rapamycin also ameliorated mitochondrial defects in cells from individuals with PARK2 mutations. Recently, 4E-BP was shown to be inhibited by the most common cause of parkinsonism, dominant mutations in LRRK2. We also found that loss of the Drosophila LRRK2 homolog activated 4E-BP and was also able to suppress Pink1 and park pathology. Thus, in conjunction with recent findings, our results suggest that pharmacologic stimulation of 4E-BP activity may represent a viable therapeutic approach for multiple forms of parkinsonism.
Parkinson's disease is the most common neurodegenerative movement disorder, affecting B1% of the elderly population. There is currently no cure and no effective disease-modifying therapy. The pathology of Parkinson's disease is principally characterized by the loss of dopaminergic neurons in the substantia nigra, which causes progressive loss of motor functions and other symptoms. The precise pathologic mechanisms remain unclear; however, the identification of several genes associated with rare, heritable forms of Parkinson's disease have highlighted putative pathogenic causes such as mitochondrial dysfunction and aberrant protein degradation 1, 2 . In addition, oxidative stress is a prominent and common feature in all forms of Parkinson's disease and probably represents a convergent toxic event leading to neuronal cell death.
Disruption of two genes, PARK2, which encodes an E3 ubiquitin ligase (Parkin), and PINK1, encoding a mitochondrially targeted kinase, results in autosomal recessive parkinsonism 2 . Recent analyses have revealed that PINK1 and Parkin act in a common pathway that maintains mitochondrial integrity [3] [4] [5] [6] . Genetic studies of the Drosophila Pink1 and park (the Drosophila homolog of PARK2) mutants, which have dopaminergic neurodegeneration, locomotor deficits and mitochondrial dysfunction, have been instrumental in understanding the pathogenesis and discovering potential protective pathways 7 . Additional components of the PINK1/Parkin pathway 8, 9 and its effects on mitochondrial dynamics 6, [10] [11] [12] are being elucidated; however, it is currently unclear how these pathologic effects may be circumvented to prevent neurodegeneration. To address this, we previously conducted a genetic screen for modifiers of Drosophila park mutants to identify factors that enhance or suppress the pathology induced by park mutations. This approach can identify factors acting directly on the PINK1/Parkin pathway or indirectly, revealing parallel pathways that mediate cell-protective mechanisms. In this screen, we identified the Drosophila gene Thor, which encodes the sole ortholog of mammalian EIF4EBP1 (ref. 13 ). 4E-BP1 is an inhibitor of translation that has been implicated in mediating the survival response to various physiological stresses [14] [15] [16] .
The ability of a cell to elicit a rapid response to intrinsic or extrinsic stress is essential for survival. Regulated control of translation is an elaborate mechanism that allows immediate changes in gene expression from existing mRNAs. The initiation of translation is the rate-limiting step and is thus subject to precise regulation. Translation initiation is governed by the eukaryotic initiation factor 4E (eIF4E), which mediates the binding of the eIF4F complex to the mRNA 5¢ cap structure 16, 17 . The availability of eIF4E is regulated by eIF4E-binding proteins (4E-BPs), which bind and sequester eIF4E, preventing eIF4F complex formation and translation. In turn, the activity of 4E-BPs is tightly regulated by phosphorylation. Hypo-phosphorylated 4E-BP1 binds eIF4E with high affinity; however, on hyper-phosphorylation, 4E-BP1 dissociates from eIF4E, allowing 5¢ cap-dependent translation to occur. The conserved TOR signaling pathway is central to the regulation of 4E-BP phosphorylation. TOR is activated in response to numerous stimuli, including the activation of the PI3K/Akt1 pathway, after which it phosphorylates 4E-BP and other factors promoting cap-dependent translation. Thus, TOR signaling coordinates cell growth and metabolism in response to physiological changes 18, 19 .
Inhibition of cap-dependent translation by 4E-BP is essential for survival under stress conditions. 4E-BP has been shown to be important for survival under a wide variety of stresses, including starvation, oxidative stress, unfolded protein stress and immune challenge [20] [21] [22] [23] [24] . Many cellular stressors result in the rapid cessation of cap-dependent translation, which is accompanied by the concomitant promotion of cap-independent translation of essential pro-survival factors 14, 25 . Switching the translational profile from cap-dependent to cap-independent provides the cell with the ability to rapidly respond to environmental changes and transient stresses.
We found that the loss of 4E-BP function in Drosophila markedly reduces park and Pink1 mutant viability. In contrast, overexpression of 4E-BP is sufficient to suppress all pathologic phenotypes in these mutants, including neurodegeneration. We also found that activation of 4E-BP by pharmacologic inhibition of its negative regulator TOR with rapamycin is able to elicit a similar protective effect in vivo. Notably, rapamycin treatment is also able to ameliorate mitochondrial defects in cell lines from individuals with PARK2-mutant Parkinson's disease. Furthermore, we provide, to the best of our knowledge, the first evidence that the Drosophila homolog of LRRK2 genetically interacts with Pink1/park mutants, which is consistent with a recent report showing that LRRK2 regulates the activity of 4E-BP 26 . Thus, our results suggest that modulating 4E-BP activity represents a viable therapeutic target for modifying the pathologic process and may be applicable to multiple forms of parkinsonism.
RESULTS

4E-BP genetically interacts with the Parkin/PINK1 pathway
In a screen for park modifiers, we previously recovered a P-element neighboring the Drosophila gene Thor, which encodes the sole ortholog of mammalian EIF4EBP1 (ref. 13 ). We refer to the endogenous gene as Thor, as per established FlyBase nomenclature, and transgenes or the protein are referred to as 4E-BP (see Online Methods for more details on the transgene used). To confirm and extend the analysis of this genetic interaction, we obtained an independent, previously characterized, null allele of Thor (Thor 2 ) to cross with null mutations in park (park 25 ) and Pink1 (Pink1 B9 ).
In contrast with park and Pink1 mutants, homozygous Thor 2 mutants are fully viable and fertile and show no overt phenotypes under normal conditions 20 . To our surprise, we found that Thor 2 ; park 25 double mutants were essentially lethal ( Supplementary Fig. 1 ). Rare escapers were occasionally recovered but died shortly after eclosing as adults. This synthetic lethality could be rescued by targeted expression of a 4E-BP wild-type transgene ( Supplementary Fig. 1 ). Similarly, we found a substantial reduction in the viability of Thor 2 ; Pink1 B9 double mutants ( Supplementary Fig. 1 ), although the degree of interaction was not as severe. Heterozygous combinations of Thor 2 and park 25 or Pink1 B9 mutations had no effect on viability.
4E-BP overexpression suppresses park and Pink1 phenotypes Because the loss of 4E-BP is detrimental to park and Pink1 mutants, we reasoned that increased 4E-BP expression may have a protective effect. Pink1 and park mutants have locomotor deficits in flight and climbing ability, widespread muscle degeneration and mitochondrial defects. Overexpression of 4E-BP using the muscle specific 24B-GAL4 driver . (e-p) Toluidine blue-stained sections of adult thorax (original magnification, Â20) and transmission electron microscopy (TEM) images of muscle (scale bars, 1 mm) show that 4E-BP or FOXO overexpression suppressed muscle degeneration and mitochondrial defects. Abnormal mitochondrial morphology in mutants (black arrowheads) was restored (white arrowheads). Data are presented as mean ± s.e.m. Significance was determined by one-way ANOVA with Bonferroni correction (*** P o 0.001). Genotypes: +/park 25 and +/Pink1 B9 are heterozygous controls, park 25 and Pink1 B9 are homozygotes, 24B refers to a 24B-GAL4 muscle-specific driver line used to induce transgenic overexpression (4) of 4E-BP or foxo. park 25 24B and Pink1 B9 24B are homozygous mutants with a 24B-GAL4 background, but no accompanying transgenic overexpression, representing negative controls for genetic background effects.
significantly suppressed the climbing and flight defects in both park and Pink1 mutants (P o 0.001; Fig. 1a-d) . The muscle degeneration and mitochondrial disruption seen in park/Pink1 mutants was also abrogated by 4E-BP overexpression ( Fig. 1e-p) . park 25 and Pink1 B9 mutants exhibit age-related degeneration of a subset of dopaminergic neurons 4, 27 . We used the tyrosine hydroxylase-GAL4 line (THG4) to drive expression of 4E-BP in the dopaminergic neurons of park and Pink1 mutants and analyzed the number of dopaminergic neurons surviving in the protocerebral posterior lateral 1 cluster of aged flies. Notably, we found that overexpression of 4E-BP in Pink1 and park mutants was capable of significantly suppressing dopaminergic neuron loss (P o 0.05 and P o 0.001, respectively; Fig. 2a ). Consistent with a previous study 26 , there was also a loss of dopaminergic neurons in Thor 2 mutants (Fig. 2b) . Together, these findings indicate that 4E-BP is required to prevent neurodegeneration and increasing the amount of 4E-BP mediates a protective mechanism that is sufficient to prevent the pathologic consequence of loss of Parkin or PINK1.
4E-BP pathway is activated in park and Pink1 mutants
To gain insight into the status of 4E-BP activity in park and Pink1 mutants, we examined the transcriptional, translational and posttranslational state of 4E-BP. First, we quantified the relative levels of Thor transcript and found that the levels were not significantly different between mutants and wild-type flies (P ¼ 0.16; Supplementary Fig. 2 ). 4E-BP activity is regulated by altered phosphorylation state, so we examined the relative levels of phosphorylated and nonphosphorylated 4E-BP. Western blot analysis revealed that there was a significant reduction in the level of hyper-phosphorylated 4E-BP in park and Pink1 mutants (P o 0.05 and P o 0.001, respectively) and a concomitant increase in the proportion of active, nonphosphorylated 4E-BP (Fig. 3a,b) .
Under normal conditions, 4E-BP function is actively repressed by the Akt1-TOR signaling pathway; thus, the previous result suggests that this pathway itself may be downregulated in response to a loss of park and Pink1 function. To assess the broader effects of park and Pink1 mutations on the pathway that regulates 4E-BP, we examined the activity status of Akt1, an upstream regulator of 4E-BP that is itself activated by phosphorylation. The relative amount of active, phosphorylated Akt1 was markedly reduced in park and Pink1 mutants (Fig. 3c,d) , indicating a downregulation of this pathway.
Akt1 signaling inactivates the transcription factor FOXO, which regulates the expression of Thor 28, 29 . FOXO is also known to regulate the expression of a large number of stress response factors and detoxification enzymes 30, 31 and has been shown to influence lifespan and stress resistance across taxa, including Drosophila 32,33 . Thus, we sought to test whether overexpression of foxo modulated park and Pink1 mutant phenotypes. Although widespread overexpression of foxo was lethal in a wild-type background, we recovered viable park mutants overexpressing foxo; however, overexpression in a Pink1 mutant background was lethal. Notably, we found that foxo overexpression significantly rescued the flight and climbing defects (P o 0.001; Fig. 1a,b) , restored muscle integrity (Fig. 1k,l) , and prevented dopaminergic neuron loss in park mutants (Fig. 2a) to the same extent as was observed during 4E-BP overexpression.
These results indicate that the Akt1/TOR signaling pathway that regulates 4E-BP activity and global protein translation is downregulated in park and Pink1 mutants, which is typical of a stress response to promote protective mechanisms. Our genetic studies indicate that this endogenous mechanism can be ectopically further upregulated. We therefore sought to achieve this by pharmacologic inhibition of TOR signaling.
Rapamycin suppresses park and Pink1 pathology 4E-BP is negatively regulated via phosphorylation by TOR, which can be inhibited by exposure to rapamycin 34 . Therefore, we reasoned that administering rapamycin to park and Pink1 mutants could promote 4E-BP hypo-phosphorylation and confer a protective effect. Mutant and control flies were raised on normal food supplemented with either rapamycin or vehicle alone. Consistent with previous p a r k 2 5 , T H G 4 / + p a r k 2 5 , T H G 4 > 4 E -B P p a r k 2 5 , T H
, T H G 4 / + P in k 1 B 9 , T H 2 5 P in k 1 B 9 Phospho-4E-BP reports 35, 36 , we found that rapamycin treatment led to 4E-BP hypophosphorylation in vivo ( Supplementary Fig. 2) . Notably, we found that administration of rapamycin was able to suppress all pathologic phenotypes in park and Pink1 mutants (Fig. 4) . Rapamycin treatment reduced the appearance of thoracic indentations, a surrogate marker for flight muscle degeneration (Fig. 4a) , suppressed the climbing deficits, and prevented the muscle degeneration and mitochondrial defects (Fig. 4b,d-i) . Notably, we also found that dopaminergic neurodegeneration was completely suppressed in park and Pink1 mutant flies raised and aged on rapamycin-supplemented food (Fig. 4c) .
Treatment of Drosophila cells with double-stranded RNA (dsRNA) specific for park, which causes a marked reduction in park transcript and protein levels ( Supplementary Fig. 3 ), led to a significant elongation of the mitochondrial reticulum (P o 0.01; Fig. 5a ), similar to the recently reported mitochondrial elongation in fibroblasts from individuals with Parkinson's disease with PARK2 mutations 12 . Co-treatment with rapamycin effectively suppressed the mitochondrial morphology defects in park-deficient Drosophila cells (Fig. 5a) . We wanted to extend these findings to determine whether rapamycin treatment is relevant to human pathology. Rapamycin treatment of PARK2-deficient fibroblasts was also able to suppress the mitochondrial elongation and partially rescue the loss of membrane potential (Fig. 5b,c) .
The effects of rapamycin are mediated by 4E-BP Inhibition of TOR by rapamycin exerts other effects than those on 4E-BP (for example, promoting autophagy). Autophagy has received much attention as a putative protective mechanism in neurodegenerative diseases, particularly in the clearance of misfolded, undegraded or aggregated proteins. We wished to determine whether the beneficial effects of rapamycin operate through 4E-BP-dependent or 4E-BPindependent mechanisms, or a combination of both.
To address this directly, we used a genetic approach to test whether rapamycin protection required 4E-BP. park and Pink1 mutants were combined with Thor 2 null mutations to generate double mutants and administered rapamycin or vehicle as before. Rapamycin treatment again improved viability and reduced the presence of thoracic indentations in park and Pink1 mutants (Fig. 6a,b) ; however, in a homozygous Thor 2 mutant background, the suppression of park and Pink1 phenotypes was completely abolished (Fig. 6a,b) . In contrast, attenuating the induction of autophagy by RNA interference (RNAi)-mediated knockdown of Atg5 (Supplementary Fig. 3 ) had no effect on the rapamycin-induced suppression of park and Pink1 phenotypes (Fig. 6c,d ). These results indicate that the beneficial effects of rapamycin require the activity of 4E-BP but not autophagy. Consistent with this, we also found that rapamycin did not prevent degeneration of dopaminergic neurons in Thor 2 mutants (Fig. 2b) .
4E-BP activity upregulates the detoxifying enzyme GstS1
Active 4E-BP induces the rapid cessation of cap-dependent translation to promote the upregulation of stress response factors such as antioxidants and chaperones. The precise changes to the proteomic signature induced on 4E-BP activation are currently unknown, but are likely to be numerous. We previously showed that transgenic overexpression of the antioxidant and detoxifying enzyme GstS1 is sufficient to suppress park phenotypes 27 ; therefore, it seemed possible that upregulation of GstS1 may constitute part of the 4E-BP-mediated stress response. Assessing the protein levels of GstS1, we found that they were increased on either transgenic overexpression of 4E-BP or the administration of rapamycin (Fig. 7) . Together with our previous findings, this supports a role for the upregulation of stress response factors by activation of 4E-BP. Further work to elucidate the exact translational changes induced by 4E-BP activity will provide important insight into the molecular mechanisms that promote neuroprotection.
Genetic interaction with Drosophila LRRK2 homolog Dominant pathogenic mutations in LRRK2 are known to cause aberrant increase in its kinase activity 37, 38 . Recently, it was shown that 4E-BP is a substrate of human LRRK2 and the Drosophila ortholog (Lrrk) and that pathogenic mutations cause hyper-phosphorylation of 4E-BP in vivo, leading to reduced oxidative stress resistance and dopaminergic neurodegeneration 26 . We therefore hypothesized that a loss of LRRK2 would lead to hypo-phosphorylated 4E-BP, which should promote a protective response.
Consistent with a previous report 26 , we found that homozygous Lrrk e03680 loss-of-function mutations cause a decrease in the amount of phosphorylated 4E-BP compared with wild type (Fig. 8a,b) , although this does not detectably decrease further in park and Pink1 mutant adults. Lrrk mutants have normal flight and mildly reduced climbing ability; however, we found that combining homozygous Lrrk e03680 with park and Pink1 mutations rescued the dopaminergic neuron loss, and flight and climbing deficits of park and Pink1 mutants (Fig. 8c-e) . These results are consistent with normal LRRK function, in part, negatively regulating survival programs necessary for dopaminergic neuron survival.
DISCUSSION
We used Drosophila as a model system to uncover genetic suppressors to understand the pathogenic mechanisms and to indentify putative therapeutic pathways for Parkinson's disease. We previously identified Thor, the sole Drosophila homolog of mammalian EIF4EBP1, as a genetic modifier of park. Here we further characterized the genetic interaction of Thor with park and Pink1. Although loss-of-function mutations in Thor markedly decrease park and Pink1 mutant viability, overexpression of 4E-BP is able to suppress Pink1 and park mutant phenotypes, including degeneration of dopaminergic neurons. These results suggest that 4E-BP acts to mediate or promote a survival response implemented on the loss of Parkin or PINK1.
4E-BP1 is an inhibitor of 5¢ cap-dependent protein translation, which is known to be important in cellular response to changes in environmental conditions such as altered nutrient levels and various physiological stresses 14, 25 . It has been demonstrated that Drosophila 4E-BP is important for survival under a wide variety of stresses, including starvation, oxidative stress, unfolded protein stress and immune challenge [20] [21] [22] [23] . Such a response pathway represents a likely target for possible manipulation by therapeutics. Our genetic evidence supports this idea and we therefore sought to validate whether this represented a viable therapeutic target.
4E-BP activity is regulated post-translationally by the TOR signaling pathway. Activated TOR hyper-phosphorylates 4E-BP, inhibiting it and leading to the promotion of 5¢ cap-dependent translation 18, 39 . Rapamycin is a small molecule inhibitor of TOR signaling and has been shown to lead to 4E-BP hypo-phosphorylation in vitro and in vivo 35, 36 . Our genetic evidence suggested that administration of rapamycin to park and Pink1 mutants should relieve 4E-BP inhibition and confer a protective effect. Exposing mutant flies to rapamycin during development caused an increase in hypo-phosphorylated 4E-BP and was sufficient to suppress all pathologic phenotypes, including muscle degeneration, mitochondrial defects and locomotor ability. Continued administration of rapamycin during aging also completely suppressed progressive degeneration of dopaminergic neurons.
To validate this pathway as a viable target for therapy, we extended our studies to human tissue. There is growing evidence that mitochondrial dysfunction is a key pathologic event across the spectrum of parkinsonism. We and others have reported mitochondrial defects in a number of cell lines derived from individuals with PARK2 mutations 12, 40 . We found that rapamycin was also capable of ameliorating ; p a r k 2 5 + / T h o r 2 ; p a r k 2 5 T h o r 2 ; p a r k 2 5 P in k 1 B 9 ; + / + P in k 1 B 9 ; + / T h o r 2 P in k 1 B 9 ; T h o r 2 p a r k 2 5 ; d a / + P in k 1 B 9 ; d a / + p a r k 2 5 + / T h o r 2 ; p a r k 2 5 T h o r 2 ; p a r k 2 5 P in k 1 B 9 ; + / + P in k 1 B 9 ; + / T h o r 2 P in k 1 B 9 ; mitochondrial bioenergetic and morphological defects in cells lines from PARK2-deficient individuals with Parkinson's disease. Thus, our results provide strong support for the proposition that modulating 4E-BP-mediated translation by pharmaceuticals such as rapamycin can be efficacious in vivo and is relevant to human pathophysiology. TOR signaling regulates a number of downstream effectors other than 4E-BP: for example, upregulation of S6 kinase promoting protein synthesis and cell proliferation and downregulation of autophagy, probably through inhibition of ATG1 (ref. 19) . The coordinated regulation of these pathways serves to optimize cellular activity in response to vital changes such as nutrient availability and environmental stresses. Stimulation of autophagy under nutrient-deprived conditions is a survival mechanism that recycles essential metabolic components, but this mechanism also promotes the degradation of aggregated or misfolded proteins. Thus, the potential therapeutic effects of rapamycin have been widely promoted as a strategy for combating a number of neurodegenerative diseases, including Parkinson's disease, primarily because of its perceived role in promoting autophagic clearance of aggregated proteins. However, recent studies have provided compelling evidence that the pro-survival effects of rapamycin can be mediated in the absence of autophagy by reducing protein translation 41, 42 . We found that genetic ablation of 4E-BP was sufficient to completely abrogate any beneficial effects of rapamycin in vivo, whereas inhibiting Atg5 (ref. 43) , an important mediator of autophagy 44 , does not diminish the efficacy of rapamycin-mediated protection. Together, these results indicate that, in this instance, the major protective effects of rapamycin treatment are mediated through regulated protein translation, with little or no contribution from autophagy.
A switch from cap-dependent to cap-independent translation is likely to effect widespread changes in the proteome, particularly the induction of pro-survival factors such as chaperones, anti-oxidants and detoxifying enzymes. In support of this, we found that transgenic or rapamycin-induced 4E-BP activation leads to increased protein levels of GstS1, a major detoxification enzyme in Drosophila 45 . Notably, we previously found that transgenic overexpression of Drosophila GstS1 is able to suppress dopaminergic neuron loss in park mutants 27 . Elucidating the global changes in response to 4E-BP activation will be crucial for understanding the exact molecular mechanisms of neuroprotection, but this change currently remains unresolved.
The potential importance of 4E-BP modulation as a therapeutic target is underscored by recent findings that report that the most common genetic causes of Parkinson's disease, dominant mutations in LRRK2, inhibit 4E-BP function through direct phosphorylation 26 . Expression of these mutations causes disruption of dopaminergic neurons in Drosophila 26 and mice 46 ; however, similar to our results, overexpression of 4E-BP can circumvent the pathogenic effects of mutant Lrrk and prevent neurodegeneration 26 in Drosophila. We found that the loss of Drosophila Lrrk leads to the activation of 4E-BP and can suppress pathology in Pink1 and park mutants. These data further support a link between LRRK2 and 4E-BP activity and a common cause of Parkinson's disease. Thus, our results indicate that promoting 4E-BP activity may be beneficial for preventing neurodegeneration in multiple forms of parkinsonism. Because 4E-BP activity can be manipulated by small molecule inhibitors such as rapamycin, this pathway represents a viable therapeutic target. It will be particularly interesting to determine whether rapamycin is efficacious in ameliorating pathologic phenotypes in the recently reported Lrrk2 transgenic mouse model 46 , but further studies will be necessary to determine whether pharmacologic modulation of 4E-BP function is therapeutically relevant in all forms of parkinsonism, including sporadic Parkinson's disease.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureneuroscience/.
Note: Supplementary information is available on the Nature Neuroscience website.
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